Catalog No.
DHE26399
Description
Polatuzumab vedotin (Polivy) is an ADC consisting of a CD79b-directed antibody and Monomethyl auristatin E (MMAE) that can be used in combination with bendamustine and rituximab for the treatment of adult patients with at least two relapses or refractory diffuse large B-cell lymphoma. Polatuzumab vedotin binds to CD79b and is internalized by tumor cells. MMAE is cleaved from cells by lysosomal protease and promotes tumor cell apoptosis by inhibiting microtubule formation.
Species reactivity
Human
Clonality
Monoclonal
Target
CD79b
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Purification
Purified by Ion Exchange Chromatography.
Applications
Research Grade Biosimilar
Form
Liquid
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Polivy
Clone ID
Polatuzumab vedotin-piiq
For research use only. Not for human or drug use.
